Pharmaceutical Privately-held Portuguese drugmaker BIAL today announced positive results from a Phase III, randomized, double-blind, active- and placebo-controlled, parallel group study (BIPARK-I) evaluating opicapone (BIA 9-1067), a novel once-daily catechol-O-methyltransferase (COMT) inhibitor for use as adjunctive therapy in levodopa-treated Parkinson’s disease patients. 19 March 2015